Xerosis
7
1
1
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (7)
Novel Skin Barrier Product Versus Petrolatum for Skin Barrier Dysfunction
Clinical Therapeutic Potential of Novel Microbiome LP-51 on Xerosis Individual Based on Xerosis-microbiome Index
Efficacy Study of Cosmetic Product on Xerosis Induced by Systemic Anticancer Treatments
Combined Effect of Acitretin and Narrow Band Ultraviolet B on Vitiligo Repigmentation
The Role of Skin Care Regimen in Skin Health
Skin Barrier Biophysical Properties and Clinical Appearance After Moisturizer in Dry Skin
Safety and Efficacy of SQIN™ on Xerosis in Adults With Mobility Problems and Paralysis